Last €65.53 EUR
Change Today -0.48 / -0.73%
Volume 847.6K
As of 3:45 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

fresenius medical care ag & (FME) Snapshot

Open
€66.00
Previous Close
€66.01
Day High
€66.17
Day Low
€64.93
52 Week High
01/27/15 - €66.86
52 Week Low
06/9/14 - €46.56
Market Cap
20.4B
Average Volume 10 Days
1.0M
EPS TTM
€3.48
Shares Outstanding
311.2M
EX-Date
05/16/14
P/E TM
21.3x
Dividend
€0.77
Dividend Yield
1.17%
Current Stock Chart for FRESENIUS MEDICAL CARE AG & (FME)

Related News

No related news articles were found.

fresenius medical care ag & (FME) Related Businessweek News

No Related Businessweek News Found

fresenius medical care ag & (FME) Details

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides renal dialysis products and services. It offers dialysis treatment, and related laboratory and diagnostic services through its network of 3,250 outpatient dialysis clinics in approximately 45 countries worldwide; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the U.S. for the hospitalized ESRD patients and for patients suffering from acute kidney failure. The company also provides pharmacy services, such as delivery and supply of renal medications to patients at homes or to dialysis clinics directly; vascular access surgery services; and manufactures and distributes products for the treatment of end-stage renal disease (ESRD). In addition, it offers laboratory services that include blood, urine, and other bodily fluid testing services; and hemodialysis (HD) machines, modular components for dialysis machines, polysulfone dialyzers, bloodlines, HD solutions and concentrates, needles, connectors, machines for water treatment, data administration systems, dialysis chairs, phosphate binders, iron products, and other renal drug products. Further, the company provides peritoneal dialysis systems and solutions for continuous ambulatory peritoneal dialysis and automated peritoneal dialysis therapy; and adsorbers, which are filters used in other extracorporeal therapies; and distributes specific instruments for vascular access, as well as other supplies, such as bandages, clamps, and injections. It sells its products to clinics, hospitals, and specialized treatment clinics through direct sales forces, local sales forces, independent distributors, dealers, and sales agents. The company was founded in 1996 and is headquartered in Bad Homburg, Germany.

97,327 Employees
Last Reported Date: 11/4/14
Founded in 1996

fresenius medical care ag & (FME) Top Compensated Officers

Chairman of the Management Board for Freseniu...
Total Annual Compensation: $1.7M
Chief Financial Officer of Fresenius Medical ...
Total Annual Compensation: $1.0M
Chief Executive Officer of Fresenius Medical ...
Total Annual Compensation: $1.5M
Chief Executive Officer of Asia Pacific Divis...
Total Annual Compensation: $1.1M
Chief Executive Officer of Global Manufacturi...
Total Annual Compensation: $924.0K
Compensation as of Fiscal Year 2013.

fresenius medical care ag & (FME) Key Developments

Fresenius Medical Care AG & Co. KGAA Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 09:45 AM

Fresenius Medical Care AG & Co. KGAA Presents at UniCredit und Kepler Cheuvreux 14th German Corporate Conference, Jan-19-2015 09:45 AM. Venue: Villa Kennedy, Kennedyallee 70, D-60596 Frankfurt, Germany. Speakers: Michael Brosnan, Chief Financial Officer of Fresenius Medical Care Management AG and Member of the Management Board for Fresenius Medical Care Management AG.

Fresenius Medical Care AG & Co. KGAA Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:00 AM

Fresenius Medical Care AG & Co. KGAA Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-13-2015 09:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Robert Maurice Powell, Chairman of the Management Board for Fresenius Medical Care Management AG and Chief Executive Officer of Fresenius Medical Care Management AG.

CytoSorbents Corporation Announces Strategic Partnership with Fresenius Medical Care AG & CO KGaA

CytoSorbents Corporation announced that they have entered into a multi-country strategic partnership with Fresenius Medical Care AG & CO KGaA to commercialize CytoSorbents' CytoSorb® therapy. Under the terms of the agreement, Fresenius Medical Care will have the exclusive rights to distribute CytoSorb® for critical care applications in France, Poland, Sweden, Denmark, Norway, and Finland. The partnership will allow Fresenius Medical Care to offer an innovative and easy to use blood purification therapy for removing cytokines in patients that are treated in the intensive care unit. To promote the success of CytoSorb®, Fresenius will also engage in the ongoing clinical development of the product. This includes the support and publication of a number of small case series and patient case reports as well as the potential for future larger, clinical collaborations. This multi-year agreement is subject to annual minimum guaranteed orders of CytoSorb® to maintain exclusivity.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FME:GR €65.53 EUR -0.48

FME Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $266.54 USD -6.71
CareFusion Corp $59.30 USD -0.30
DaVita HealthCare Partners Inc $75.06 USD -1.08
Shire PLC 4,854 GBp -44.00
Toray Industries Inc ¥1,010 JPY +13.70
View Industry Companies
 

Industry Analysis

FME

Industry Average

Valuation FME Industry Range
Price/Earnings 21.3x
Price/Sales 1.4x
Price/Book 2.4x
Price/Cash Flow 21.9x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS MEDICAL CARE AG &, please visit www.fmc-ag.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.